TOPIROXOSTAT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H8N6
Molecular Weight	248.2428
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3

InChI

InChIKey=UBVZQGOVTLIHLH-UHFFFAOYSA-N

InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)

HIDE SMILES / InChI

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33460
Curator's Comment: Description was created based on several sources, including http://www.pharmacodia.com/yaodu/html/v1/chemicals/ee14c41e92ec5c97b54cf9b74e25bd99.html

Topiroxostat was approved by Pharmaceuticals Medical Devices Agency of Japan (PMDA) on June 28, 2013. It was co-developed and marketed as Uriadec®/Topiloric® by Sanwa Kagaku Kenkyusho & Fuji Yakuhin. Topiroxostat is a xanthine oxidase inhibitor. Xanthine oxidase (XO) is a type of enzyme that generates reductive oxygen species, which catalyze the oxidation of hypoxanthine to xanthine and can further catalyze the oxidation of xanthine to uric acid. Topiroxostat could reduce the production of uric acid in the body through the inhibition of xanthine oxidase. It is usually used for the treatment of gout and hyperuricemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Xanthine dehydrogenase 32 Target ID: CHEMBL1929 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27038523	Inhibitor 8297		5.3 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperuricemia 8 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33460	Primary		Approved 8429	URIADEC Approved Use Used for the treatment of gout and hyperuricemia Launch Date 2013
Gout 28 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33460	Primary		Approved 8429	URIADEC Approved Use Used for the treatment of gout and hyperuricemia Launch Date 2013

PubMed

Title	Date	PubMed
Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.	2006 Nov	16914512
Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.	2007 Dec	17761779
FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys.	2009 Jun	19336671
Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].	2009 Nov 1	19783139
Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.	2011 May	20936465

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, the initial dose is started with 20mg of the active ingredient at a time, twice a day, in the morning and in the evening, and the dosage may be gradually increased according to your blood uric acid levels. The maintenance dose is usually 1 tablet (60mg) at a time, twice a day. The dosage may be adjusted according to the disease, age or symptoms. The maximum dosage is 80mg at a time, twice a day. This preparation contains 60mg of the active ingredient in a tablet.

Route of Administration: Oral

In Vitro Use Guide

IC50 values (50% inhibitory concentrations) of topiroxostat against plasma XOR activity were 5.84 nmol/l in mice.

Name

Type

Language

TOPIROXOSTAT

Official Name

English

FYX-051

Code

English

TOPIROXOSTAT [MI]

Common Name

English

Topiroxostat [WHO-DD]

Common Name

English

topiroxostat [INN]

Common Name

English

4-(5-(PYRIDIN-4-YL)-1H-1,2,4-TRIAZOL-3-YL)PYRIDINE-2-CARBONITRILE

Systematic Name

English

TOPIROXOSTAT [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1637